Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Crinetics falls after mid-stage trial data adrenal disorder therapy
Crinetics Pharmaceuticals (CRNX) stock fell after Phase 2 results for its experimental drug atumelnant for congenital adrenal hyperplasia. Read more here.
Science Daily14h
Harnessing microwave flow reaction to convert biomass into useful sugars
Researchers have developed a new process that uses microwave flow reaction and recyclable solid catalysts to efficiently hydrolyze polysaccharides into simple sugars. The developed device utilizes a ...
Hippocratic AI secures $141m in Series B funding
Healthcare-focused AI startup Hippocratic AI has closed its Series B financing round, raising $141m, led by venture capital ...
Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.
Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
marketinference23h
Catalyst Pharmaceuticals Settles Patent Dispute
Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...
MM&M1d
Rx Rundown: Verdiva, Johnson & Johnson, Transcarent and more
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.